Skip to content

Use of Fish Oils to Reduce Recurrence of Atrial Fibrillation Following DC Cardioversion

Use of Fish Oils to Reduce Recurrence of Atrial Fibrillation Following DC Cardioversion.

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00232219
Enrollment
200
Registered
2005-10-04
Start date
2003-01-31
Completion date
2013-11-30
Last updated
2015-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation

Brief summary

The purpose of this study is to investigate whether fish oil supplements may be beneficial in preventing the recurrence of atrial fibrillation after cardioversion. Atrial fibrillation is a heart condition which can sometimes be successfully treated by a cardioversion. Cardioversion involves resetting the heart back to normal with the use of electric current. There is a tendency for the atrial fibrillation to recur , days weeks or even months after the cardioversion. Fish oil supplements may be of benefit to patients with heart problems Recent evidence suggests that fish oils may be beneficial to patients with rhythm disturbances.

Interventions

DRUGFish oil

Sponsors

Melbourne Health
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

* Patients with persistent Atrial Fibrillation on Warfarin.

Exclusion criteria

* paroxysmal atrial fibrillation with self terminating episodes. * left atrial size\>6.0cm * myocardial infarction in the previous 6 months. * contraindications to amiodarone use . * cardiac surgery in the previous 3 months . * an acute reversible illness contributing to the development of af * a QTc interval \> 480ms. * pregnancy

Design outcomes

Primary

MeasureTime frame
Recurrence of atrial fibrillation followed cardioversion1 year

Other

MeasureTime frame
Safety and tolerability1 year

Countries

Australia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026